Literature DB >> 18201177

The utility of MRI for the screening and staging of breast cancer.

N Patani1, K Mokbel.   

Abstract

INTRODUCTION &
BACKGROUND: Contrast-enhanced magnetic resonance imaging (MRI) of the breast has been recently introduced as a potential clinical tool for the detection, diagnosis, staging and management of breast cancer. In this article, we consider the established and evolving roles of MRI with particular reference to screening in high risk women and staging of the primary tumour. Controversies are discussed in the context of the tumour biology and natural history of breast cancer.
METHODS: Articles were identified by searches of PubMed and MEDLINE up to October 2007.
RESULTS: Contrast-enhanced MRI is an effective tool for screening women at high risk of breast cancer. However, randomized trials have yet to demonstrate a reduction in mortality. MRI can also facilitate local staging, in particular, the evaluation of ipsilateral multicentric or multifocal lesions and synchronous contralateral disease which may be 'missed' by conventional imaging. However, efficacy with respect to clinically relevant and patient oriented end-points has yet to be addressed in the context of clinical trials.
CONCLUSIONS: In women at high risk of breast cancer, screening MRI should be used in conjunction with published guidelines. In women with newly diagnosed breast cancer, the utility of MRI is less clearly defined and should be restricted to selected cases within the multidisciplinary setting.

Entities:  

Mesh:

Year:  2008        PMID: 18201177     DOI: 10.1111/j.1742-1241.2007.01677.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  4 in total

1.  Extra-mammary findings in breast MRI.

Authors:  Pierluigi Rinaldi; M Costantini; P Belli; M Giuliani; E Bufi; R Fubelli; D Distefano; M Romani; L Bonomo
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

2.  Longitudinal and multi-echo transverse relaxation times of normal breast tissue at 3 Tesla.

Authors:  Richard A E Edden; Seth A Smith; Peter B Barker
Journal:  J Magn Reson Imaging       Date:  2010-10       Impact factor: 4.813

3.  Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.

Authors:  S U Dhar; H P Cooper; T Wang; B Parks; S A Staggs; S Hilsenbeck; S E Plon
Journal:  Breast Cancer Res Treat       Date:  2011-04-05       Impact factor: 4.872

4.  Frequency and Clinical Significance of Extramammary Findings on Breast Magnetic Resonance Imaging.

Authors:  Sneha Phadke; Alexandra Thomas; Limin Yang; Catherine Moore; Chang Xia; Mary C Schroeder
Journal:  Clin Breast Cancer       Date:  2015-08-28       Impact factor: 3.225

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.